Dapa Met Xr 10/1000 Mg Tablet – Extended-Release Therapy for Type 2 Diabetes
Dapa Met Xr 10/1000 Mg Tablet – Extended-Release Therapy for Type 2 Diabetes
Description
Dapa Met Xr 10/1000 Mg Tablet – Sustained Dual Mechanism for Optimal Glycemic Control
Dapa Met Xr 10/1000 Mg Tablet is an extended-release combination medication featuring dapagliflozin 10mg, an SGLT2 inhibitor, and metformin 1000mg, a biguanide, specifically formulated for adults with type 2 diabetes mellitus. It functions by inhibiting glucose reabsorption in the kidneys to expel excess sugar through urine while simultaneously decreasing glucose production in the liver and enhancing insulin utilization, leading to steady blood sugar management throughout the day with reduced dosing frequency. This prescription tablet is particularly beneficial for patients requiring long-acting therapy to minimize peaks and troughs in glucose levels, also providing added protection against heart failure and chronic kidney disease progression when used as part of a comprehensive treatment plan including diet and exercise.
